Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltux-AMR: Siltuximab for Antibody-Mediated Rejection After Lung Transplantation
NCT06990711Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of siltuximab in antibody mediated rejection (AMR) (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Incidence of CTCAE >= grade 3 at 90 days. Started Nov 2025; status: recruiting.
02
Drugs
siltuximab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT06990711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990711.